BAP1突变定义具有纤维板层样特征且PKA激活的肝细胞癌同质亚群
该研究对151例肝脏肿瘤(126例HCC、15例FLC、10例混合型FLC/HCC)进行RNAseq及全基因组/全外显子测序,发现17例肿瘤聚类为独立亚群,均携带BAP1失活突变或易位。BAP1-HCC好发于女性、无慢性肝病者,预后较FLC差,且免疫热、祖细胞特征、无DNAJB1-PRKACA融合,80%存在PRKACA获得合并PRKAR2A缺失导致PKA通路激活。
要点
- BAP1失活定义具有纤维板层样特征的HCC亚群,需与FLC鉴别。
- BAP1-HCC好发于无慢性肝病女性,预后较FLC差。
- BAP1-HCC免疫热且PKA激活,或可试用PKA抑制剂或免疫调节剂。
核心结论
- BAP1驱动的HCC亚群具有纤维板层样特征和PKA通路失调,可能是BAP1肿瘤与DNAJB1-PRKACA FLC临床和组织学相似性的根源。
研究设计与样本
- 对151例肝脏肿瘤(126例HCC、15例FLC、10例混合型FLC/HCC)进行RNAseq和全基因组或全外显子测序,并用Western blot验证基因组发现,结果用TCGA数据库验证。
主要发现
- 多数混合型FLC/HCC的RNAseq聚类为17例肿瘤的稳健亚群,均携带BAP1失活突变或易位。
- BAP1-HCC较非BAP1 HCC显著富集于女性、无慢性肝病和纤维化肿瘤,但患者年龄更大且预后较FLC差。
- BAP1肿瘤免疫热、显示祖细胞特征、无DNAJB1-PRKACA融合,且几乎无CTNNB1、TP53和TERT启动子突变。
- 80%的BAP1肿瘤显示19p13的PRKACA染色体获得合并3p21的PRKAR2A缺失,导致mRNA和蛋白水平PRKACA/PRKAR2A比值升高。
临床怎么用
- 对具有纤维板层样特征的HCC应检测BAP1状态以识别该亚群。
- BAP1-HCC患者年龄较大且预后较FLC差,需加强随访。
- PKA激活和T细胞浸润提示可考虑PKA抑制剂或免疫调节剂治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: DNAJB1-PRKACA fusion is a specific driver event in fibrolamellar carcinoma (FLC), a rare subtype of hepatocellular carcinoma (HCC) that occurs in adolescents and young adults. In older patients, molecular determinants of HCC with mixed histological features of HCC and FLC (mixed-FLC/HCC) remain to be discovered. METHODS: A series of 151 liver tumors including 126 HCC, 15 FLC, and 10 mixed-FLC/HCC were analyzed by RNAseq and whole-genome- or whole-exome sequencing. Western blots were performed to validate genomic discoveries. Results were validated using the TCGA database. RESULTS: Most of the mixed-FLC/HCC RNAseq clustered in a robust subgroup of 17 tumors, which all had mutations or translocations inactivating BAP1, the gene encoding BRCA1-associated protein-1. Like FLC, BAP1-HCC were significantly enriched in females, patients with a lack of chronic liver disease, and fibrotic tumors compared to non-BAP1 HCC. However, patients were older and had a poorer prognosis than those with FLC. BAP1 tumors were immune hot, showed progenitor features and did not show DNAJB1-PRKACA fusion, while almost none of these tumors had mutations in CTNNB1, TP53 and TERT promoter. In contrast, 80% of the BAP1 tumors showed a chromosome gain of PRKACA at 19p13, combined with a loss of PRKAR2A (coding for the inhibitory regulatory subunit of PKA) at 3p21, leading to a high PRKACA/PRKAR2A ratio at the mRNA and protein levels. CONCLUSION: We have characterized a subgroup of BAP1-driven HCC with fibrolamellar-like features and a dysregulation of the PKA pathway, which could be at the root of the clinical and histological similarities between BAP1 tumors and DNAJB1-PRKACA FLCs. LAY SUMMARY: Herein, we have defined a homogeneous subgroup of hepatocellular carcinomas in which the BAP1 gene is inactivated. This leads to the development of cancers with features similar to those of fibrolamellar carcinoma. These tumors more frequently develop in females without chronic liver disease or cirrhosis. The presence of PKA activation and T cell infiltrates suggest that these tumors could be treated with PKA inhibitors or immunomodulators.
引用
- Hirsch TZ, Negulescu A, Gupta B, et al. BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA. J Hepatol. 2019. PMID: 31862487. doi:10.1016/j.jhep.2019.12.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。